(s)-2-(cyclobutylamino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)isonicotinamide attenuates rankl-induced osteoclast differentiation by inhibiting nf-b nuclear translocation

HIGHLIGHTS

• who: Mina Ding and collaborators from the BioMedical Sciences Graduate Program (BMSGP), Chonnam National University, Gwangju, Republic of Korea have published the article: (S)-2-(Cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide Attenuates RANKL-Induced Osteoclast Differentiation by Inhibiting NF-B Nuclear Translocation, in the Journal: (JOURNAL)
• what: This study investigates the underlying molecular mechanisms of EPZ015866 on osteoclast differentiation. This study shows that EPZ015866, a derivative of EPZ015666, has a better therapeutic effect on osteoporosis than EPZ015666. The authors demonstrated that EPZ015866 and EPZ015666, known inhibitors of PRMT5, inhibit . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.